Morphine-induced locomotor and neurochemical stimulation is enhanced in transgenic mice with impaired glucocorticoid receptor function

Journal of Neuroendocrinology

Volumn 8, Issue 2, 1996, Pages 93-97

  Spanagel, Rainer ^a   Stöhr, Thomas ^a   Barden, Nicholas ^b   Holsboer, Florian ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Hypothalamus pituitary adrenal system; Locomotor activity; Mesolimbic dopamine system; Morphine

Indexed keywords

CORTICOTROPIN; GLUCOCORTICOID RECEPTOR; MORPHINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG ABUSE; DRUG EFFECT; DRUG SENSITIVITY; HYPOPHYSIS ADRENAL SYSTEM; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; MORPHINE ADDICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

3,4-DIHYDROXYPHENYLACETIC ACID; ADRENOCORTICOTROPIC HORMONE; ANIMALS; BRAIN CHEMISTRY; CORTICOSTERONE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; LIMBIC SYSTEM; MALE; MICE; MICE, TRANSGENIC; MORPHINE; MOTOR ACTIVITY; NARCOTICS; RATS; RECEPTORS, GLUCOCORTICOID; STIMULATION, CHEMICAL;

EID: 0029986308     PISSN: 09538194     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2826.1996.tb00828.x     Document Type: Article

References (34)

1. Stolerman I. (1992). Drugs of abuse: Behavioural principles, methods and terms. Trends Pharmacol Sci. 13: 170-176.
2. Cador M, Dulluc J, Mormède P. (1993). Modulation of the locomotor response to amphetamine by corticosterone. Neuroscience. 56: 981-988.
3. Fahlke C, Engel JA, Eriksson CJP, Hard E, Söderpalm B. (1994). Involvement of corticosterone in the modulation of ethanol consumption in the rat. Alcohol. 11: 195-202.
4. Goeders NE, Wagner LA, Marshall SB, Guarin GF. (1993). The effects of metyrapone on intravenous cocaine self-administration in rats. Soc Neurosci Abst. 19: 1860.
5. Marinelli M, Piazza PV, Deroche V, Maccari S, Le Moal M, Simon H. (1994). Corticosterone circadian secretion differentially facilitates dopamine-mediated psychomotor effects of cocaine and morphine. J Neurosci 14: 2724-2731.
6. Piazza PV, Maccari S, Deminière J-M, Le Moal M, Mormède P, Simon H. (1991). Corticosterone levels determine individual vulnerability to amphetamine self-administration. Proc Natl Acad Sci USA. 88: 2088-2092.
7. Piazza PV, Deroche V, Deminère J-M, Maccari S, Le Moal M, Simon H. (1993). Corticosterone in the range of stress-induced levels possesses reinforcing properties: Implication for sensation-seeking behaviors. Proc Natl Acad Sci USA. 90. 11738-11742
8. Evans RM, Arriza JL. (1989). A molecular framework for the action of glucocorticoid hormones in the central nervous system. Neuron. 2: 1105-1112.
9. Trapp T, Rupprecht R, Castrén M, Reul JMHM, Holsboer F. (1994). Heterodimerization between mineralcorticoid and glucocorticoid receptor: A new principle of glucocorticoid action in the CNS. Neuron. 13: 1547-1462.
10. Pepin M-C, Pothier F, Barden N. (1992). Impaired type II glucocorticoid-receptor function in mice bearing antisense RNA transgene. Nature. 335: 725-728.
11. Pepin M-C, Beaulieu S, Barden N. (1989). Antidepressants regulate glucocorticoid receptors mRNA concentrations in primary neural cultures. Mol Brain Res. 6: 77-83.
12. Pepin M-C, Pothier F, Barden N. (1992). Antidepressant drug action in a transgenic mouse model of the endocrine changes seen in depression. Mol Pharmacol. 42: 991-995.
13. Stec I, Barden N, Reul JMH, Holsboer F. (1994). Dexamethasone nonsuppresion in transgenic mice expressing antisense RNA to the glucocorticoid receptor J Psychiatr Res. 28: 1-5.
14. Richard D, Chapdelaine S, Deshaies Y, Pepin M-C, Barden N. (1993). Energy balance and lipid metabolism in transgenic mice bearing an antisense GCR gene construct. Am J Physiol. 265: 146-150.
15. Montkowski A, Barden N, Wotjak C, Stec I, Ganster J, Meaney M, Engelmann M, Reul JMHM, Landgraf R, Holsboer F. (1996). Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function. J Neuroendocrinology. (in press).
16. Wise RA, Bozarth MA. (1987). A psychomotor stimulant theory of addiction. Psychological Rev. 94: 469-492.
17. Wise RA, Rompre PP. (1989). Brain dopamine and reward. Ann Rev Psychol. 40: 191-225.
18. Härfstrand A, Fuxe K, Cintra A, Agnati LF, Zini I, Wikström A, Okret S, Yu Z, Goldstein M, Steinbusch H, Verhofstad A, Gustafsson J. (1986) Glucocorticoid receptor immunoreactivity in monoaminergic neurons of rat brain. Proc Natl Acad Sci USA 83: 9779-9785.
19. Ronken E, Mulder AH, Schoffelmeer ANM. (1994). Glucocorticoid and mineralocorticoid receptors differentially modulate cultured dopaminergic neurons of rat ventral mesencephalon. Eur J Pharmacol. 263: 149-156.
20. Gysling K, Wang RY. (1983). Morphine-induced activation of A10 dopamine neurons in the rat brain. Brain Res. 277: 119-127.
21. Matthews RT, German DC. (1984). Electrophysiological evidence for excitation of rat ventral tegmental area dopaminergic neurons by morphine. Neuroscience. 11: 617-626.
22. Di Chiara G, Imperato A (1988). Opposite effects of mu and kappa opioid agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther. 244: 1067-1080.
23. Leone P, Pocock D, Wise RA. (1991). Morphine-dopamine interaction: ventral tegmental morphine increases nucleus accumbens dopamine release. Pharmacol Biochem Behav. 39: 469-472.
24. Wood, PL. (1994). Interrelationships of opioids, dopaminergic, cholinergic, and GABAergic pathways in the central nervous system. In: Herz A, ed. Opioids, 625-643. Springer, Heidelberg.
25. Roth RH, Murrin LC, Walters JR. (1976). Central dopaminergic neurons: Effects of alterations in impulse flow on accumulation of dihydroxyphenylacetic acid. Eur J Pharmacol. 36: 163-171.
26. Kalivas PW, Widerlöv E, Stanley D, Breese G, Prange AJ. (1983). Enkephalin action on the mesolimbic system: a dopamine-dependent and a dopamine-independent increase in locomotor activity. J. Pharmacol Exp Ther. 227: 229-237.
27. Wood PL. (1983). Opioid regulation of CNS dopaminergic pathways: A review of methodology, receptor types, regional variations and species differences. Peptides. 4: 595-601.
28. Boschi G, Launay N, Rips R, Scherrmann J-M. (1995). Brain microdialysis in the mouse. J. Pharmacol Toxicol Methods 33: 29-33.
29. Westerink BHC, Justice JB Jr. (1991). Microdialysis compared with other in vivo release models. In: Robinson TE, Justice JP Jr, eds. Techniques in the behavioral and neural sciences; Microdialysis in the Neurosciences, 23-47. Elsevier, Amsterdam.
30. Wood PL, Altar CA. (1988). Dopamine release in vivo from nigro-striatal. mesolimbic, and mesocortical neurons: Utility of 3-methoxytyramine measurements. Pharmacol Rev. 40: 163-187.
31. Beaulieu S, Rousse I, Gratton A, Barden N, Rochford J. (1993). Behavioral characterization of a transgenic mouse model of impaired type II glucocorticoid receptor function. Soc Neurosci Abst. 19: 498
32. Palkovits M, Brownstein MJ. (1988). Maps and Guide to Microdissection of the Rat Brain. Elsevier, New York.
33. Jakubovic A, Fu D, Fibinger HC. (1987). Factors affecting the stability and separation of biogenic amines and their metabolites. J. Pharmacol Methods 17: 1-4.
34. Spanagel R, Herz A, Shippenberg TS. (1990). The effects of opioid peptides on dopamine release in the nucleus accumbens: An in vivo microdialysis study. J Neurochem. 55: 1734-1740.